Opella launches as independent company

Sanofi now keeps a significant shareholding with a 48.2 per cent stake and Bpifrance owning a 1.8 per cent stake.

The leadership of Opella at the announcement. Photo: Opella

As the third-largest global player in the €190 billion over-the-counter and vitamins, minerals, and supplements space, Opella is set to lead in one of the most dynamic, resilient corners of healthcare where megatrends like ageing populations, digital access, and self-care demand are rewriting the rulebook.

Opella is headquartered in France. Its 100 brands including Allegra, Dulcolax, Enterogermina, or Doliprane are already trusted names in homes around the world. The self-care environment is still far too complex, leaving most people who suffer without treatment. Opella is grounded in science, with deep consumer obsession and a commitment to sustainability, to offer solutions that help people access the care they deserve.

Opella shared plans and vision in Vietnam. Photo: Opella

Julie Van Ongevalle, Opella president and CEO said, “Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health – simply, confidently, and on their terms.”

Valentina Belcheva, MSc Pharm, PhD, general manager of Opella Vietnam and Cambodia added, "Vietnam is a market of immense potential with 100 million people and a growing demand for self-care. Through strategic partnerships, we are driving awareness and access to make self-care as simple as it should be. On this new path, we will deliver on our promise to achieve better health for individuals, families, and communities.”

In Vietnam, Opella has offices in Ho Chi Minh City and Hanoi, as well as a manufacturing site with advanced and automated technology in Saigon Hi Tech Park.

Sanofi brings world's first modular concept manufacturing facility to Singapore Sanofi announced on December 4 the inauguration of its state-of-the-art manufacturing facility, Modulus, in Singapore, marking a significant milestone in its commitment to delivering innovative healthcare solutions globally.

Health Ministry, Sanofi strengthen cooperation in pharmaceutical industry development Sanofi-Aventis Vietnam Co., Ltd. is seeking to strengthen cooperation with the Ministry of Health (MoH) to increase access to new medicines for Vietnamese people and develop the pharmaceutical industry.

Earendil Labs, Sanofi Ink Global License Deal for Next-Gen Autoimmune Therapies Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.